Last reviewed · How we verify
NCT05184686
Effects of Electromagnetic Field and Noise on Resting Electroencephalogram of Health Subjects
NA trial testing noise expose in Electroencephalography in 128 participants. Completed in 15 November 2023.
15 October 2022
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 128 |
| Start date | 6 November 2021 |
| Primary completion | 15 October 2022 |
| Estimated completion | 15 November 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- noise expose
- RF expose
Conditions studied
- Electroencephalography — all drugs for Electroencephalography →
- Electromagnetic — all drugs for Electromagnetic →
- Noise Exposure — all drugs for Noise Exposure →
Sponsor
Xijing Hospital
Who can join
Adults 18 to 30, male only, with Electroencephalography or Electromagnetic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With the development of science and technology, there are more and more electromagnetic and noise factors in the working and living environment. These two factors often exist together, and their impact on people may interact. Scalp EEG is a classic nerve detection technology, which can reflect the functional state of the brain in a non-invasive and real-time manner. This project intends to use EEG technology to study the effects of electromagnetism and noise on human brain function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05184686
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Electroencephalography
Currently open trials in the same condition.
- NCT06725550 — Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0 · NA · recruiting
- NCT06694402 — The Effects of Focal Muscle Vibration Combined With Exercise on Sensorimotor Activity in Individuals With Chronic Subacr · NA · recruiting
- NCT07037186 — Burst Suppressions in Diabetic Elderly · active not recruiting
- NCT06698705 — The EEG Study Under Remimazolam Anesthesia in Children · recruiting
- NCT06237101 — Remifentanil Effect on Burst Suppression Ratio · NA · recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05184686 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 23 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05184686.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing